Cardinal Health, Inc. CAH
220.22
(2.40)
(1.08%)
as of 25 Sep
- Market cap
- $51.6B
- P/E
- 30.3×
Follow CAH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Cardinal Health, Inc. (CAH) EBITDA
Cardinal Health, Inc.'s EBITDA for fiscal 2026 was $3.6B, up 16.4% from $3.1B in fiscal 2025. Over the past ten years it has ranged from −$3.2B (fiscal 2020) to $3.6B (fiscal 2026) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. Cardinal Health, Inc. ranks 3rd of 10 Medical Distribution companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $3.6B | 16.44% |
| FY2025 | $3.1B | 56.94% |
| FY2024 | $2.0B | 35.25% |
| FY2023 | $1.4B | 1,598.82% |
| FY2022 | $85.0M | (93.23%) |
| FY2021 | $1.3B | — |
| FY2020 | −$3.2B | — |
| FY2019 | $3.1B | 164.25% |
| FY2018 | $1.2B | (59.18%) |
| FY2017 | $2.8B | (8.48%) |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $970.0M | 28.14% |
| Mar 2026 | $757.0M | (19.55%) |
| Dec 2025 | $941.0M | 4.44% |
| Sep 2025 | $901.0M | 41.44% |
| 42 more quarters | Free account |
Against its own ten years
Low −$3.2B
High $3.6B
Ten-year median
$2.3B
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| MCK McKesson Corporation compare | $7.3B |
| COR Cencora, Inc. compare | $4.1B |
| CAH Cardinal Health, Inc. | $3.6B |
| HSIC Henry Schein, Inc. compare | $1.0B |
| ACH Accendra Health, Inc. compare | $285.4M |
| YI 111, Inc. Sponsored ADR compare | −$3.3M |
| COSM Cosmos Health Inc. compare | −$16.9M |
| FOCL FocalTherics compare | −$25.3M |
| AHG Akso Health Group Sponsored ADR compare | −$30.3M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CAH
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement